Lipinski, Michael J Forrestal, Brian J Iantorno, Micaela Torguson, Rebecca Waksman, Ron

A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials. - 2018

Available in print through MWHC library: 2002 - present

BACKGROUND: Recent studies suggest the Orsiro sirolimus-eluting stent (O-SES), which has ultrathin struts with a biodegradable sirolimus-eluting polymer coating, performed better than contemporary drug-eluting stents (DES). We performed a meta-analysis to compare clinical outcomes for all randomized controlled trials (RCTs) of O-SES vs contemporary DES. METHODS/MATERIALS: PubMed, Cochrane CENTRAL, and meeting abstracts were searched for all RCTs comparing O-SES with contemporary DES. Pooled estimates of longest available clinical outcomes at a minimum of one-year follow-up, presented as odds ratios (OR) [95% confidence intervals], were generated with random-effect models. RESULTS: We included 8 RCTs with a total of 11,176 patients (5444 O-SES and 5732 contemporary DES [3537 EES, 1295 ZES, and 1264 BP-BES) with a mean age of 65+/-11, 74% were male, 40% underwent PCI for stable angina, and 56% for ACS. We assessed outcomes comparing O-SES vs. everolimus-eluting stents, vs. permanent-polymer DES, and vs. all DES including biodegradable-polymer DES. Orsiro performed comparably in all categories with a trend toward a reduction in myocardial infarction (0.83 [0.68, 1.02], p=0.07) and stent thrombosis (0.75 [0.54, 1.04], p=0.08). CONCLUSION: Overall, the Orsiro SES had similar clinical outcomes to contemporary DES with a trend toward reduction in myocardial infarction and stent thrombosis. Copyright (c) 2017 Elsevier Inc. All rights reserved.



*Cardiovascular Agents/ad [Administration & Dosage]
Cardiovascular Agents/ae [Adverse Effects]
Coronary Artery Disease/dg [Diagnostic Imaging]
Coronary Artery Disease/mo [Mortality]
Coronary Artery Disease/pp [Physiopathology]
*Coronary Artery Disease/su [Surgery]
Coronary Thrombosis/et [Etiology]
Coronary Vessels/dg [Diagnostic Imaging]
Coronary Vessels/pp [Physiopathology]
*Coronary Vessels/su [Surgery]
*Drug-Eluting Stents
Middle Aged
Myocardial Infarction/et [Etiology]
Percutaneous Coronary Intervention/ae [Adverse Effects]
*Percutaneous Coronary Intervention/is [Instrumentation]
Percutaneous Coronary Intervention/mo [Mortality]
Prosthesis Design
Randomized Controlled Trials as Topic
Risk Factors
*Sirolimus/ad [Administration & Dosage]
Sirolimus/ae [Adverse Effects]
Time Factors
Treatment Outcome

MedStar Heart & Vascular Institute
MedStar Heart & Vascular Institute

Journal Article

Powered by Koha